CD1D and neoplasm: Tumor-elevated sphingomyelin (Table 3; Figure 5), a sphingolipid enriched in the mammalian plasma membrane, has been shown to weakly stimulate iNKT cells through a mono-acylated derivative, whereas the di-acylated form is predominantly reported to act as an inhibitor when presented on CD1d (92, 93).